<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074810</url>
  </required_header>
  <id_info>
    <org_study_id>VS-6766-203</org_study_id>
    <nct_id>NCT05074810</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of VS-6766 + Sotorasib in G12C NSCLC Patients</brief_title>
  <acronym>RAMP203</acronym>
  <official_title>A Phase 1/2 Study of VS-6766 in Combination With Sotorasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of VS-6766 in combination with sotorasib in&#xD;
      patients with G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to&#xD;
      prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, non-randomized, open-label Phase 1/2 study designed to evaluate safety&#xD;
      and tolerability and efficacy of VS-6766 in combination with sotorasib in patients with KRAS&#xD;
      G12C mutant NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: To determine RP2D for VS-6766 in combination with sotorasib</measure>
    <time_frame>From start of treatment to confirmation of RP2D; 28 days</time_frame>
    <description>Assessment of Dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: To determine the efficacy of the optimal regimen identified from Part A</measure>
    <time_frame>From start of treatment to confirmation of response; 16 weeks</time_frame>
    <description>Confirmed overall response rate per RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the safety and toxicity profile</measure>
    <time_frame>24 months</time_frame>
    <description>Treatment emergent adverse events/ treatment emergent serious adverse events - their frequency, duration and severity, lab parameters, vital signs and ECG changes based on CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Time from the first documentation of response to first documentation of progressive disease or death due to any cause, greater than or equal to 6 months</time_frame>
    <description>Time of first response to PD as assessed per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Greater than or equal to 8 weeks</time_frame>
    <description>CR and PR stable disease as assessed per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>From the time of first dose of study intervention to PD or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>From time of first dose of study intervention to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of VS 6766, sotorasib, and relevant metabolites - Tmax</measure>
    <time_frame>10 weeks</time_frame>
    <description>time of Maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of VS 6766, sotorasib, and relevant metabolites -AUC</measure>
    <time_frame>10 weeks</time_frame>
    <description>Area under plasma Concentration (AUC) 0 to t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of VS 6766, sotorasib, and relevant metabolites half-life</measure>
    <time_frame>10 weeks</time_frame>
    <description>concentration Half-life (T1/2)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>KRAS Activating Mutation</condition>
  <arm_group>
    <arm_group_label>VS-6766+sotorasib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the recommended phase 2 dose (RP2D) for VS 6766 in combination with sotorasib in G12C inhibitor naïve and exposed patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VS-6766+sotorasib - G12C inhibitor naïve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the efficacy of the RP2D identified from Part A in G12C inhibitor naïve patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VS-6766+sotorasib - G12C inhibitor exposed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the efficacy of the RP2D identified from Part A in G12C inhibitor exposed patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VS-6766 and sotorasib</intervention_name>
    <description>The RP2D of VS-6766 + sotorasib determined in Part A will be used in Part B dose expansion</description>
    <arm_group_label>VS-6766+sotorasib</arm_group_label>
    <arm_group_label>VS-6766+sotorasib - G12C inhibitor exposed</arm_group_label>
    <arm_group_label>VS-6766+sotorasib - G12C inhibitor naïve</arm_group_label>
    <other_name>AMG 510</other_name>
    <other_name>LUMAKRAS™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients ≥ 18 years of age&#xD;
&#xD;
          -  Histologic or cytologic evidence of NSCLC&#xD;
&#xD;
          -  Known G12C KRAS mutation&#xD;
&#xD;
          -  Have not received a KRAS inhibitor to be included in Part A and Part B, Cohort 1&#xD;
&#xD;
          -  Received at least 1 dose of a G12C inhibitor to be included in Part A or Part B Cohort&#xD;
             2&#xD;
&#xD;
          -  Must have received appropriate treatment with at least one prior systemic regimen, but&#xD;
             no more than 3 prior regimens, for Stage 3B-C or 4 NSCLC&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1&#xD;
&#xD;
          -  An Eastern Cooperative Group (ECOG) performance status ≤ 1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Adequate recovery from toxicities related to prior treatments&#xD;
&#xD;
          -  Agreement to use highly effective method of contraceptive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy&#xD;
&#xD;
          -  History of prior malignancy, with the exception of curatively treated malignancies&#xD;
&#xD;
          -  Major surgery within 4 weeks (excluding placement of vascular access)&#xD;
&#xD;
          -  History of treatment with a direct and specific inhibitor of MEK&#xD;
&#xD;
          -  Exposure to strong CYP3A4 inhibitors or inducers within 14 days prior to the first&#xD;
             dose and during the course of therapy&#xD;
&#xD;
          -  Symptomatic brain metastases requiring steroids or other local interventions.&#xD;
&#xD;
          -  Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy&#xD;
&#xD;
          -  Known hepatitis B, hepatitis C, or human immunodeficiency virus infection that is&#xD;
             active&#xD;
&#xD;
          -  Active skin disorder that has required systemic therapy within the past year&#xD;
&#xD;
          -  History of rhabdomyolysis&#xD;
&#xD;
          -  Concurrent ocular disorders&#xD;
&#xD;
          -  Concurrent heart disease or severe obstructive pulmonary disease&#xD;
&#xD;
          -  Inability to swallow oral medications&#xD;
&#xD;
          -  Female patients that are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop Youssoufian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Verastem Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gloria Patrick</last_name>
    <phone>781-469-1594</phone>
    <email>gpatrick@verastem.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>KRAS G12C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

